Chi-Med, AstraZeneca start phase III trial of savolitinib in papillary renal cell carcinoma
Dubbed SAVOIR, the phase 3 trial will be held globally in five to ten countries to assess the efficacy and safety of savolitinib in comparison with sunitinib. The open-label,